- Do you need definitive NASH market data?
- Succinct NASH market analysis?
- Technological insight?
- Actionable business recommendations?
Read on to discover how this definitive report can transform your own research and save you time.
The increase in prevalence of hepatic pathology and its pathophysiology have propelled the growth of the novel therapeutic studies, which has given birth to the novel therapeutic solutions such as Farnesoid X Receptor (FXR) agonists, incretins and probiotics. Most of these studies are in last phase of their clinical trials and commercialization is expected within a short period of time that could be used in treating patients with NASH.
132 quantitative tables, charts, and graphs across 145 pages
Global NASH market outlook and analysis from to 2027
Global NASH submarket forecasts and analysis from to 2027
- GFT 505
- Obeticholic Acid (INT-747)
- Simtuzumab and Liraglutide (Victoza)
- Vitamin E
Regional and National NASH market forecasts to 2027
- North America forecast to 2027:
- US forecast to 2027
- Canada forecast to 2027
- Mexico forecast to 2027
- South America forecast to 2027:
- Brazil forecast to 2027
- Argentina forecast to 2027
- Paraguay forecast to 2027
- Bolivia forecast to 2027
- Rest of South America forecast to 2027
- Europe forecast to 2027:
- Germany forecast to 2027
- UK forecast to 2027
- France forecast to 2027
- Italy forecast to 2027
- Spain forecast to 2027
- Rest of Europe forecast to 2027
- Asia-Pacific forecast to 2027
- Japan forecast to 2027
- India forecast to 2027
- China forecast to 2027
- Australia forecast to 2027
- Thailand forecast to 2027
- Rest of Asia-Pacific forecast to 2027
- Rest of World forecast to 2027:
- Middle East forecast to 2027
- Africa forecast to 2027
- Other Countries forecast to 2027
Key questions answered:
- What does the future hold for the Pharmaceutical industry with regards to Nonalcoholic Steatohepatitis (NASH)
- Where should you target your business strategy?
- Which applications should you focus upon?
- Which disruptive technologies should you invest in?
- Which companies should you form strategic alliances with?
- Which company is likely to success and why?
- What business models should you adopt?
- What industry trends should you be aware of?
- Leading Pharmaceutical companies
- R&D staff
- Business development managers
Visiongain is a trading partner with the US Federal Government.